Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy

(2020) Feihu Wang et al.   Science Advances

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

(2019) Daniel Shae et al.   Nature Nanotechnology

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy

(2018) David G. Leach et al.   BIOMATERIALS

Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy

(2018) David R. Wilson et al.   Nanomedicine-Nanotechnology Biology and Medicine

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases

(2018) Chun Gwon Park et al.   Science Translational Medicine

In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy

(2018) Chao Wang et al.   Science Translational Medicine

RecombinantListeriapromotes tumor rejection by CD8+T cell-dependent remodeling of the tumor microenvironment

(2018) Weiwen Deng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

(2018) Assaf Marcus et al.   IMMUNITY

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

(2018) Qian Chen et al.   Nature Nanotechnology

Rationale for stimulator of interferon genes–targeted cancer immunotherapy

(2017) Thaiz Rivera Vargas et al.   EUROPEAN JOURNAL OF CANCER

Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model

(2017) Shekhar K. Gadkaree et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation

(2016) Ken Takashima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Chemotherapy and immunotherapy: mapping the road ahead

(2016) Alistair M Cook et al.   CURRENT OPINION IN IMMUNOLOGY

Make better, safer biomaterials

(2016) Nicholas A. Peppas et al.   NATURE

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

(2016) D. Mathios et al.   Science Translational Medicine

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment

(2015) Giuseppe Lombardi et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Linker-determined drug release mechanism of free camptothecin from self-assembling drug amphiphiles

(2014) Andrew G. Cheetham et al.   CHEMICAL COMMUNICATIONS

Intrinsic Self-DNA Triggers Inflammatory Disease Dependent on STING

(2014) Jeonghyun Ahn et al.   JOURNAL OF IMMUNOLOGY

STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer

(2014) D. Chandra et al.   Cancer Immunology Research

Murine leukemia virus envelope gp70 is a shared biomarker for the high-sensitivity quantification of murine tumor burden

(2014) Francesca Scrimieri et al.   OncoImmunology

Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation

(2014) Lotte Spel et al.   OncoImmunology

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy

(2013) Christel Devaud et al.   MOLECULAR THERAPY

cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING

(2013) Andrea Ablasser et al.   NATURE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA

(2012) J. Wu et al.   SCIENCE

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

(2012) L. Sun et al.   SCIENCE

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors

(2009) Kazuki N. Sugahara et al.   CANCER CELL

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

(2009) Hiroki Ishikawa et al.   NATURE

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

(2008) Hiroki Ishikawa et al.   NATURE